中国新冠病毒诊疗方案纳入罗氏公司药品

by swisschambei in 工程制造

中国卫生部门周三表示,中国已将罗氏公司(Roche Holding AG, RHHBY)和日本的中外制药(Chugai Pharmaceutical Co., 4519.TO)开发的一种治疗类风湿性关节炎药物列为某些新型冠状病毒患者的正式治疗药物。国家卫生健康委员会在其最新的诊疗方案中纳入了这家瑞士制药巨头以雅美罗(Actemra)商品名销售的托珠单抗(tocilizumab)。卫健委称,这种药物适用于双肺广泛病变者及重型患者,且实验室检测IL-6水平升高者。罗氏公司对该药物的描述显示,IL-6被认为会引起细胞因子风暴,托珠单抗可以通过与IL-6的受体结合来抑制这种情况。

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

在华瑞士商务平台

SwissCham China has roughly 600 company members. Our Chamber maintains a strong relationship with the Embassy of Switzerland, Swiss Global Enterprise, Swissnex and Switzerland Tourism. As the representative of the Swiss companies established in China, our goal is to help you to increase your business and visibility, especially amongst the Sino-Swiss business community.

Become A Member

订阅简讯

  • 这个字段是用于验证目的,应该保持不变。
6月 8, 2021
Published By finance.eastmoney.com in 经济
5月 7, 2021
Published By xinhuanet.com in 工程制造
5月 7, 2021
Published By eda.admin.ch in 双边关系
4月 28, 2021
Published By finance.sina.com.cn in 旅游 / 酒店 / 零售 /
4月 14, 2021
Published By eda.admin.ch in 双边关系